Skip to main content

SENP6 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-00238

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-00238

Key Product Details

Species Reactivity

Validated:

Human

Predicted:

Bovine (100%), Mouse (100%), Rat (100%). Backed by our 100% Guarantee.

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Peptide ELISA

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Concentration

0.5 mg/ml

Product Specifications

Immunogen

Peptide with sequence C-KPKYEPNPHYHEN, from the internal region of the protein sequence according to NP_001093879.1; NP_056386.2.

Specificity

This antibody is expected to recognise both reported isoforms (NP_001093879.1; NP_056386.2).

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for SENP6 Antibody

SENP6 Antibody

Immunocytochemistry/Immunofluorescence: SENP6 Antibody [NBP1-00238] -

Immunocytochemistry/Immunofluorescence: SENP6 Antibody [NBP1-00238] - Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing nuclear and cytoplasmic staining. Actin filaments were stained with phalloidin (red) and the nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
SENP6 Antibody

Flow Cytometry: SENP6 Antibody [NBP1-00238] -

Flow Cytometry: SENP6 Antibody [NBP1-00238] - Flow cytometric analysis of paraformaldehyde fixed U2OS cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.

Applications for SENP6 Antibody

Application
Recommended Usage

Flow Cytometry

10 ug/ml

Immunocytochemistry/ Immunofluorescence

10 ug/ml

Peptide ELISA

Detection limit 1:32000

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA

Preservative

0.02% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: SENP6

Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM]

Alternate Names

EC 3.4.22.-, KIAA0797FLJ11887, Sentrin/SUMO-specific protease SENP6, sentrin-specific protease 6, SSP1KIAA0389, SUMO1/sentrin specific peptidase 6,2810017C20Rik, SUMO1/sentrin specific protease 6, SUMO-1-specific protease 1, SUSP1FLJ11355

Entrez Gene IDs

26054 (Human); 215351 (Mouse); 300860 (Rat)

Gene Symbol

SENP6

Additional SENP6 Products

Product Documents for SENP6 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SENP6 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...